Here we are at the midpoint of 2006 already. The first half stock market doesn't look pretty! The Dow is up a modest 4%. Two months ago, the Dow was up twice that level but took a tumble in May falling sharply in June and beginning to bounce back in July. The NASDAQ has really taken a hit in these first 6 months, having dropped 2%.
We all know about continue......Full article >>>
$2.7 billion. Imagine what will happen with Pfizer's Lipitor with last year's sales of $13 billion (granted this is worldwide and Pfizer's patent expiration in different parts of the world varies).
More recently, during the last 3 years, Big Pharma has experimented with a different formula called "authorized generics". Under this scenario, in advance of patent expiration, Big Pharma has ......Full article >>>
, and the completion of the Boston Scientific/Abbott Lab's acquisition of Guidant (with Abbott acquiring an equity chunk of Boston Scientific in the process). Of note, in the last week was the disposal by Pfizer of its consumer products business to J&J for over $7 billion. This includes products like Listerine and other products Pfizer had obtained in the Warner-Lambert acquisition along with Pfiz......Full article >>>
|7. Merck (MRK)||$36.43||$31.99||+14%||$ 79.5|
|8. Abbott Labs (ABT)||$43.61||$46.50||<4%>||$ 66.6|
|9. Eli Lilly (LLY)||$55.27||$56.77||<3%>||$ 62.5|
|10. Wyeth (WYE)||$44.4......|
Full article >>>
han the NASDAQ and AMEX Biotech indices. Not a pretty first half!
Big biotech stock performance 2006
|Biotech Company/Ticker||Stock Price June 30, 2006||Stock Price Jan.2, 2006||%Change||Market Cap(S B)|
|NASDAQ Biotech Index||742.87||795.32......|
Full article >>>
period and shut for 1-2 years. The current IPO window has lingered open since the 4th quarter of 2004; however it has not been a strong market, with low initial pricings and valuations. Nevertheless, it continues to remain open! We will look at this further in weeks to come!
One issue that both Big Pharma and biotech companies face: increasing resistance to high pricing on new ......
Full article >>>
Source:wistechnology.com By Michael Rosen 07/03/06
Related biology technology :
1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Business Objects to acquire La Crosse-based Firstlogic
3. Pitney Bowes and Firstlogic cancel acquisition plans
4. Tech Digest: Fiserv, IMS, Honeywell HomMed, Firstlogic
5. Tech Digest: Firstlogic, Fiserv, Red Prairie, Spectrum Brands, Associated Bank
6. J.J. Keller, Modine Manufacturing, Gustave A. Larson Co., Esker, Firstlogic, Software One
7. Pitney Bowes to acquire Firstlogic
8. Firstlogic, Informatica expand OEM partnership
9. Crate and Barrel deploys Firstlogics Information Quality Suite
10. Merkle selects Firstlogic data quality software
11. First pieces of Antarctic deep-space particle detector are in place
(Date:2/23/2017)... ... February 23, 2017 , ... ... Services portfolio to include an array of biochemical analyses critical for Lead ... to drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism ...
(Date:2/23/2017)... 23, 2017 MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017 Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... Administration (FDA) de novo clearance to begin marketing the SPEAC® System, the Brain ... for adults at home or in healthcare facilities during periods of rest. A ... Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/7/2017)... 7, 2017 MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ... Breaking Biology News(10 mins):